Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Stroke. 1987;18:325-334

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Stroke, Vol 18, 325-334, Copyright © 1987 by American Heart Association

ARTICLES

High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study


Within 3 weeks of the event, 505 patients with cerebral infarction, minor or major stroke, were randomly assigned to treatment with acetylsalicylic acid (ASA) 1.5 g/day or placebo in a double-blind clinical trial with a follow-up of 2 years in all patients. Primary events were considered to be recurrent stroke or death; secondary events, myocardial infarction and transient ischemic attack. There was no difference in stroke recurrence rate in the ASA and placebo groups (12 and 13%, respectively), nor was there any significant difference in the rate of recurrent stroke or death, first event counted (23% in the ASA and 22% in the placebo group). The risk of transient ischemic attack and myocardial infarction was not reduced in the ASA group. In the present study there was no prophylactic effect of high-dose ASA after cerebral infarction. A compilation of the major trials of ASA after transient ischemic attack and cerebral infarction is presented.


This article has been cited by other articles:


Home page
 Eur Heart JHome page
V. Thijs, R. Lemmens, and S. Fieuws
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke
Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom
Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review
Stroke, May 1, 2008; 39(5): 1638 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. S. Dhamoon, R. R. Sciacca, T. Rundek, R. L. Sacco, and M.S.V. Elkind
Recurrent stroke and cardiac risks after first ischemic stroke: The Northern Manhattan Study
Neurology, March 14, 2006; 66(5): 641 - 646.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
D. A. Vorchheimer and R. Becker
Platelets in Atherothrombosis
Mayo Clin. Proc., January 1, 2006; 81(1): 59 - 68.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
E. Touze, O. Varenne, G. Chatellier, S. Peyrard, P. M. Rothwell, and J.-L. Mas
Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis
Stroke, December 1, 2005; 36(12): 2748 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. B. Gorelick and S. M. Weisman
Risk of Hemorrhagic Stroke With Aspirin Use: An Update
Stroke, August 1, 2005; 36(8): 1801 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. Tran and S. S. Anand
Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease
JAMA, October 20, 2004; 292(15): 1867 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
J. Matias-Guiu, J. M. Ferro, J. Alvarez-Sabin, F. Torres, M. D. Jimenez, A. Lago, T. Melo, and D. C. Tong
Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction: The TACIP Study: A Randomized, Double-Blind, Multicenter Trial * Can Aspirin Ever Be Surpassed for Stroke Prevention?
Stroke, April 1, 2003; 34(4): 840 - 848.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
A. G. Thrift, H. M. Dewey, R. A.L. Macdonell, J. J. McNeil, and G. A. Donnan
Incidence of the Major Stroke Subtypes: Initial Findings From the North East Melbourne Stroke Incidence Study (NEMESIS)
Stroke, August 1, 2001; 32(8): 1732 - 1738.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
T. J. Tegos, E. Kalodiki, S.-S. Daskalopoulou, and A. N. Nicolaides
Stroke: Epidemiology, Clinical Picture, and Risk Factors: Part I of III
Angiology, October 1, 2000; 51(10): 793 - 808.
[Abstract] [PDF]

Home page
 CirculationHome page
E. H. Awtry and J. Loscalzo
Aspirin
Circulation, March 14, 2000; 101(10): 1206 - 1218.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. S. Johnson, S. F. Lanes, C. E. Wentworth III, M. H. Satterfield, B. L. Abebe, and L. W. Dicker
A Metaregression Analysis of the Dose-Response Effect of Aspirin on Stroke
Arch Intern Med, June 14, 1999; 159(11): 1248 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
A. G Thrift, J. J McNeil, A. Forbes, and G. A Donnan
Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study
BMJ, March 20, 1999; 318(7186): 759 - 764.
[Abstract] [Full Text]

Home page
 JAMAHome page
J. He, P. K. Whelton, B. Vu, and M. J. Klag
Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials
JAMA, December 9, 1998; 280(22): 1930 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
BMJ, April 25, 1998; 316(7140): 1303 - 1309.
[Full Text]

Home page
 StrokeHome page
H. Nishimura, H. Naritomi, Y. Iwamoto, H. Tachibana, and M. Sugita
In Vivo Evaluation of Antiplatelet Agents in Gerbil Model of Carotid Artery Thrombosis
Stroke, June 1, 1996; 27(6): 1099 - 1104.
[Abstract] [Full Text]

Home page
 StrokeHome page
R. G. Hart and M. J.G. Harrison
Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke
Stroke, April 1, 1996; 27(4): 585 - 587.
[Full Text]

Home page
 Arch NeurolHome page
P. B. Gorelick
Stroke Prevention
Arch Neurol, April 1, 1995; 52(4): 347 - 355.
[Abstract] [PDF]

Home page
 NEJMHome page
H. J.M. Barnett, M. Eliasziw, and H. E. Meldrum
Drugs and Surgery in the Prevention of Ischemic Stroke
N. Engl. J. Med., January 26, 1995; 332(4): 238 - 248.
[Full Text] [PDF]

Home page
 BMJHome page
Antiplatelet Trialists
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
BMJ, January 8, 1994; 308(6921): 81 - 106.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
J. L. Wilterdink and J. D. Easton
Vascular Event Rates in Patients With Atherosclerotic Cerebrovascular Disease
Arch Neurol, August 1, 1992; 49(8): 857 - 863.
[Abstract] [PDF]

Home page
 Vasc MedHome page
B. Aspey and M. Harrison
Sex differences in the antithrombotic effectiveness of aspirin
Vascular Medicine, September 1, 1990; 1(2): 113 - 119.
[PDF]

Home page
 PERSPECT VASC SURG ENDOVASC THERHome page
G. P. Clagett
Antithrombotic Drugs and Vascular Surgery
Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1990; 3(2): 79 - 102.
[PDF]


Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1987 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.